BMI1 Recombinant Monoclonal Antibody

BMI1 serves as a critical component of the Polycomb Repressive Complex 1, functioning as an epigenetic regulator that silences genes involved in cell cycle control, senescence, and self-renewal. This protein has emerged as a significant focus in cancer biology, where its overexpression correlates with tumor progression and stem cell maintenance, making it an essential target for researchers investigating oncogenic mechanisms and cellular reprogramming.

This recombinant monoclonal antibody, generated from clone 1F2 in rabbit host, offers the reproducibility and consistency that demanding experimental workflows require. Because the antibody sequence is defined and produced recombinantly, you can expect uniform performance across lots, eliminating the variability that can complicate long-term studies or multi-site collaborations. Affinity purification ensures high specificity for your BMI1 detection needs.

Validation data demonstrates robust performance across multiple applications. In Western blot analysis, this antibody reliably detects BMI1 across diverse human cell lines including HeLa, 293, K562, THP-1, U87, and U251, working effectively at dilutions from 1:500 to 1:5000. The observed band at 45 kDa runs slightly higher than the predicted 37 kDa molecular weight, a shift commonly attributed to post-translational modifications such as phosphorylation or ubiquitination that regulate BMI1 activity in vivo. For immunohistochemistry applications, the antibody has been validated in paraffin-embedded human liver cancer and lung cancer tissues at 1:50 to 1:200 dilutions using citrate buffer antigen retrieval, providing clear nuclear staining patterns consistent with BMI1 localization.

Whether you are exploring epigenetic regulation, characterizing cancer stem cell populations, or investigating Polycomb-mediated gene silencing, this antibody provides a dependable tool for your research.